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BACKGROUND
Adeno-associated virus (AAV)–mediated gene therapy is under investigation as a thera-
peutic option for persons with hemophilia A. Efficacy and safety data include 3 years 
of follow-up after a single administration of AAV5-hFVIII-SQ.
METHODS
We report durable efficacy, long-term safety, and clinical and biologic results in 15 
adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received 
a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII 
level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, 
and biologic markers of AAV transduction for up to 3 years.
RESULTS
Three years after infusion, two participants (one who had received 6×1012 vector genomes 
[vg] per kilogram of body weight and one who had received 2×1013 vg per kilogram) had 
factor VIII expression of less than 1 IU per deciliter, as assessed on chromogenic assay. 
Seven participants (who had received 6×1013 vg per kilogram) had a median factor VIII 
expression of 20 IU per deciliter; the median number of annualized treated bleeding events 
was 0, and the median use of exogenous factor VIII was reduced from 138.5 infusions to 
0 infusions per year. Bleeding in all target joints (major joints with ≥3 bleeding events 
within 6 months) in this cohort resolved (≤2 bleeding events within 12 months). Two years 
after infusion, six participants (who had received 4×1013 vg per kilogram) had a median 
factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events 
was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions 
per year. Bleeding in target joints resolved in five of six participants. The factor VIII phar-
macodynamic profiles reflected cellular turnover in the blood and molecular events lead-
ing to episomal DNA stabilization for persistent expression, findings that are consistent 
with previous observations in two model systems. Transgene-derived human factor VIII 
(hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor develop-
ment, thromboses, deaths, or persistent changes in liver-function tests were observed.
CONCLUSIONS
Gene therapy with AAV5-hFVIII-SQ vector in participants with hemophilia A resulted 
in sustained, clinically relevant benefit, as measured by a substantial reduction in an-
nualized rates of bleeding events and complete cessation of prophylactic factor VIII use 
in all participants who had received 4×1013 vg per kilogram or 6×1013 vg per kilogram 
of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, 
NCT02576795; EudraCT number, 2014 - 003880 - 38.)
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Adeno-associated virus (AAV)–medi-ated gene therapy is increasingly recog-nized for its potential to treat many 
monogenic diseases, including hemophilia A and 
B, by means of delivery of complementary DNA 
encoding functional factor VIII or factor IX pro-
teins, respectively. To date, a single administra-
tion of AAV-mediated investigational therapy has 
shown clinical improvements for 1 year with the 
use of an AAV serotype 5 vector (AAV5) for hemo-
philia A.1
Here, we describe 2-year and 3-year safety 
and efficacy data after the administration of 
AAV5-hFVIII-SQ (valoctocogene roxaparvovec) in 
men with severe hemophilia A. In addition to 
providing clinical safety and efficacy data, this 
research contributes to a mechanistic under-
standing of the variability observed in gene 
therapy studies,2-6 thus providing insights into 
mechanisms of DNA persistence and durable 
expression.
Me thods
Vector Construct
Owing to the large size of the factor VIII gene 
relative to the packaging capacity of AAV of ap-
proximately 4.7 kb,7 the AAV5-hFVIII-SQ expres-
sion cassette contains a B-domain–deleted (SQ 
variant) human factor VIII transgene and a small 
efficient promoter,8 manufactured as described 
previously.1 At approximately 5 kb, the condensed 
expression cassette is incompletely packaged into 
each AAV capsid and requires a complementary 
vector particle for annealing to form full-length, 
expression-competent, double-stranded DNA epi-
somes in cell nuclei (Fig. S3 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org).9
Study Design and Assessments
A phase 1–2 dose-escalation, safety, and efficacy 
study was initiated in June 2015 as described 
previously1; the protocol (including the statisti-
cal analysis plan) is available at NEJM.org. The 
study was designed by the sponsor, BioMarin 
Pharmaceutical, with input from the authors, 
who vouch for the accuracy and completeness 
of the data and for the adherence of the study to 
the protocol. Writing assistance was provided 
by the sponsor.
A total of 15 adult male participants with 
severe hemophilia A were enrolled. The cutoff 
date for all data reported here was April 1, 2019.
The 14 participants who were using prophy-
lactic factor VIII replacement therapy were re-
quired to discontinue prophylactic infusions at 
the time of study enrollment, but participants 
were permitted to administer factor VIII therapy 
themselves in the event of a bleeding episode 
during the study. All the participants were hos-
pitalized and observed for 24 hours after the 
infusion of AAV5-hFVIII-SQ at the following 
doses: cohort 1 included Participant 1, who re-
ceived 6×1012 vector genomes (vg) per kilogram 
of body weight; cohort 2 included Participant 2, 
who received 2×1013 vg per kilogram; cohort 3 
included Participants 3 through 9, who received 
6×1013 vg per kilogram; and cohort 4 included 
Participants 10 through 15, who received 4×1013 vg 
per kilogram. Dose escalation was monitored, 
such that the administration of the doses in 
each participant occurred only after requisite 
safety checks in previous participants, as de-
scribed previously.1
As specified in the protocol, prophylactic glu-
cocorticoids were to be administered in all sub-
sequent participants if the alanine aminotrans-
ferase level after infusion reached 1.5 times the 
baseline value in any participant who received a 
dose. This occurred in Participant 3, and so all 
remaining six participants in the cohort that 
received 6×1013 vg per kilogram (cohort 3) re-
ceived prophylactic glucocorticoids at a dose of 
40 mg per day, starting 3 weeks after infusion; 
the dose was then tapered. Participants received 
glucocorticoid therapy for at least 15 weeks. After 
an amendment to the protocol, the requirement 
for glucocorticoid prophylaxis was removed, so 
participants who received 4×1013 vg per kilogram 
(cohort 4) were given glucocorticoids, at an initial 
dose of 60 mg per day, only in response to an 
elevation in the alanine aminotransferase level.
R esult s
Long-Term Safety of AAV5-hFVIII-SQ
The characteristics of the participants are de-
scribed in Table 1 and in Table S1. All the par-
ticipants had at least one adverse event (Tables 
S2 and S3), and no participants withdrew from 
the study. The most common adverse event was 
an elevation of the alanine aminotransferase level, 
with 14 reported events (13 events of grade 1 
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and 1 event of grade 2) in 11 participants. Indi-
vidual elevations of the alanine aminotransferase 
level are detailed in Figure 1 and in Figure S1. Two 
elevations were assessed by the investigator as 
being not related to treatment, and all the events 
were characterized as being mild, nonserious, 
and transient. None of the enzyme elevations 
were accompanied by cholestatic markers, nor 
were the criteria for Hy’s law (hepatocellular 
damage with jaundice but no cholestasis, a risk 
factor for hepatic failure) met by any participant. 
Elevations in the alanine aminotransferase level 
were managed with glucocorticoids as described 
in the Methods section.
The first participant in cohort 3 (Participant 3) 
had an elevation in the alanine aminotransferase 
level, so prophylactic glucocorticoids were ad-
ministered in the remaining participants in that 
cohort. In cohort 4, glucocorticoids were used in 
an “on-demand” manner, only in response to 
elevations of the alanine aminotransferase level 
in four of the six participants.
Glucocorticoids were not administered to 
Participants 1, 2, 10, and 13. Glucocorticoids 
were initiated at a dose of 60 mg per day after 
the alanine aminotransferase level was elevated 
to 1.5 times the baseline value in Participants 3, 
6, 9, 11, and 12; glucocorticoids were also initi-
ated after the alanine aminotransferase level was 
elevated to 1.5 times the upper limit of the nor-
mal range in Participants 14 and 15. Participants 
4, 5, 7, and 8 received prophylactic glucocorticoids 
with oral prednisone, initiated at a dose of 40 mg 
per day, 3 weeks after the infusion, for a period 
of 4 weeks; glucocorticoids were slowly tapered, 
for a total of at least 15 weeks of therapy.
As specified in the protocol, investigators 
could adjust glucocorticoid treatment schedules 
on the basis of alanine aminotransferase levels. 
In general, the use of prophylactic glucocorti-
coids was associated with a delayed time until 
the first elevation of the alanine aminotransfer-
ase level and a shorter duration of having the 
alanine aminotransferase level above the upper 
limit of the normal range than was observed 
with on-demand glucocorticoid use.
Consistent with previously reported findings,1 
no apparent association was noted between ele-
vation of the alanine aminotransferase level and 
anticapsid T-cell response (see the Immune Re-
sponse Monitoring section in the Supplementary 
Appendix).10,11 No participant reported symptoms 
that were suggestive of liver dysfunction in con-
junction with an elevated alanine aminotransfer-
ase level or that showed any long-term effect on 
liver function. The γ-glutamyltransferase enzyme 
levels were monitored as a sensitive indicator of 
hepatotoxicity, and no safety signal emerged.
Three participants reported serious adverse 
events during the study. Participant 13 was hos-
pitalized for observation after grade 2 pyrexia 
developed along with myalgia and headache 
within 24 hours after the administration of 
AAV5-hFVIII-SQ. This serious adverse event was 
characterized by the investigator as being related 
to treatment on the basis of temporal proximity 
to the infusion, and the symptoms resolved 
within 48 hours after the participant received 
acetaminophen. Participants 3 and 6 had serious 
adverse events associated with preexisting hemo-
philic arthropathies that led to hospitalizations 
for elective total knee-replacement surgeries; both 
events were characterized by investigators as not 
being related to treatment.
Long-Term Clinical Effectiveness  
of AAV5-hFVIII-SQ
Three-Year Follow-up in Cohorts 1 and 2
The one participant in cohort 1 (who had received 
6×1012 vg per kilogram) and the one participant in 
cohort 2 (who had received 2×1013 vg per kilo-
gram) continued to have factor VIII expression 
levels below 1 IU per deciliter, as assessed on 
chromogenic assay. Monitoring is ongoing for 
both participants.
Three-Year Follow-up in Cohort 3
The seven participants in cohort 3, who had re-
ceived 6×1013 vg per kilogram, had the following 
mean factor VIII activity levels as measured by 
chromogenic assay at the end of years 1, 2, and 3: 
Figure 1 (facing page). Individual Profiles for Participants 
6, 7, and 8.
Factor VIII activity levels (blue bars), factor VIII use 
(see color key for reasons), alanine aminotransferase 
(ALT) levels (yellow lines), and glucocorticoid use 
(green bar below each graph) are shown over time for 
Participants 6, 7, and 8. These participants were in co-
hort 3, in which they received 6×1013 vector genomes 
(vg) per kilogram of body weight. Factor VIII activity 
was assessed by means of chromogenic assay. The 
dashed line indicates the upper limit of the normal 
range (ULN) for ALT. Profiles for all study participants 
are shown in Figure S1 in the Supplementary Appendix.
n engl j med 382;1 nejm.org January 2, 2020 33
AAV5-hFVIII-SQ Gene Ther apy for Hemophilia A
Fa
ct
or
 V
II
I A
ct
iv
ity
 (I
U
/d
l)
A
LT
 (U
/l
ite
r)
240
200
220
140
180
160
120
80
60
20
100
40
0
300
240
270
210
180
120
90
30
150
60
0
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 152144
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 152144
Week of Visit
G
lu
co
co
rt
ic
oi
d
D
os
e
(m
g/
da
y)
B Participant 7
A Participant 6
Fa
ct
or
 V
II
I A
ct
iv
ity
 (I
U
/d
l)
A
LT
 (U
/l
ite
r)
240
200
220
140
180
160
120
80
60
20
100
40
0
300
240
270
210
180
120
90
30
150
60
0
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 152144
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 152144
Week of Visit
G
lu
co
co
rt
ic
oi
d
D
os
e
(m
g/
da
y)
C Participant 8
Fa
ct
or
 V
II
I A
ct
iv
ity
 (I
U
/d
l)
A
LT
 (U
/l
ite
r)
240
200
220
140
180
160
120
80
60
20
100
40
0
300
240
270
210
180
120
90
30
150
60
0
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 152 160144
0 408 4816 24 32 56 64 72 80 88 96 104 112 120 128 136 160152144
Week of Visit
G
lu
co
co
rt
ic
oi
d
D
os
e
(m
g/
da
y)
Factor VIII use — surgery or procedureBleeding
Factor VIII activity ALT (6–43 U/liter)Factor VIII use — one-time prophylaxis Factor VIII use — treatment for other
Factor VIII use — treatment for bleeding
ULN
ULN
ULN
60 40
40 35 30 25
20
10
5
30 20 15 10
5
30 60 50
40
30
20
10
5
2.
5
40 35 30 25 25
20 10
15 155 5
20 1030
n engl j med 382;1 nejm.org January 2, 202034
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Figure 2. Factor VIII Levels over Time in Cohorts 3 and 4.
Shown are the factor VIII activity levels in cohort 3 (Panel A) and cohort 4 (Panel B). Weeks on the x axis were windowed by ±2 weeks 
(4-week window) up to week 104 and by ±4 weeks (8-week window) thereafter. The y axis represents factor VIII values as determined on 
chromogenic assay (blue) and on one-stage assay (orange). The relationship between assay values is consistent with a previously reported 
increase by a factor of 1.65 in the results on the one-stage assay as compared with results on the chromogenic assay.1 At week 32, one 
participant in cohort 3 did not have a factor VIII activity level available. The horizontal line within the boxes shows the median value, and 
the diamond the mean value (symbols may overlap). The upper and lower box boundaries represent the 25th and 75th percentiles, respec-
tively; I bars represent the minimum and maximum values. Factor VIII activity levels below the limit of quantification were imputed as 
1.5 IU per deciliter on the chromogenic assay or 0.5 IU per deciliter on the one-stage assay. Factor VIII activity levels within a 72-hour 
 interval since the last infusion of factor VIII were excluded. Note that the y axes in Panels A and B are not equal.
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64 IU per deciliter (median, 60 IU per deciliter), 
36 IU per deciliter (median, 26 IU per deciliter), 
and 33 IU per deciliter (median, 20 IU per deci-
liter), respectively (Figs. 1 and 2 and Fig. S2). 
Factor VIII expression changed as a function of 
time and the peak factor VIII level reached; the 
mean factor VIII expression decreased by 43% 
over the course of year 2 and by 10% over the 
course of year 3. The results on the one-stage 
assay consistently showed factor VIII levels that 
were approximately 1.6 times as high as those 
observed on chromogenic assay, as reported pre-
viously.1 At the ends of years 1, 2, and 3, the 
mean factor VIII levels according to the one-
stage assay were as follows: 104 IU per deciliter 
(median, 89 IU per deciliter), 59 IU per deciliter 
(median, 46 IU per deciliter), and 52 IU per deci-
liter (median, 30 IU per deciliter), respectively, 
with a nonhemophilic value defined as a level 
greater than 40 IU per deciliter.
The mean annualized rate of bleeding events 
decreased by 96%, from a mean (±SD) of 
16.3±15.7 events per year (median, 16.5 events 
per year) at baseline to 0.7±1.6 events per year 
(median, 0.0 events per year) at the end of year 
3 (Fig. 3). In the year before study entry, only one 
participant who was receiving prophylaxis was 
free from participant-reported breakthrough 
bleeding events that led to additional factor VIII 
treatment. At the end of study year 3, a total of 
six participants (86%) were free from bleeding 
events. All the participants in this cohort had 
full resolution of bleeding in target joints (or 
arthropathy)12 by year 2. (Target joints are major 
joints with ≥3 bleeding events within 6 months; 
bleeding in target joints is considered to be re-
solved if there are ≤2 bleeding events within 12 
months.)
In the year before study entry, the mean an-
nualized number of factor VIII infusions per 
participant was 136.7±22.4 (median, 138.5); at the 
end of year 3, the mean annualized use of exog-
enous factor VIII decreased by 96% to a mean of 
5.5±9.4 infusions (median, 0.0 infusions) (Fig. 3). 
A total of 98% of the factor VIII infusions after 
post-administration week 5 were reported by 
Participants 3 and 6, in association with two 
total knee-replacement surgeries that had been 
necessitated by preexisting hemophilic arthropa-
thies. A total of 11 treated bleeding events were 
reported after week 5, with 10 of these events 
occurring in Participant 6, who had the lowest 
factor VIII expression after the infusion.
Two-Year Follow-up in Cohort 4
The six participants in cohort 4, who had re-
ceived 4×1013 vg per kilogram, had a mean factor 
VIII activity level of 21.0 IU per deciliter (medi-
an, 23 IU per deciliter) at the end of year 1 and 
15 IU per deciliter (median, 13 IU per deciliter) 
at the end of year 2 (Figs. 1 and 2 and Fig. S1). 
The level decreased by 30% over the course of 
year 2 and followed a trajectory similar to that 
seen in cohort 3. According to the one-stage as-
say, the mean factor VIII levels were 31 IU per 
deciliter (median, 32 IU per deciliter) at the end 
of year 1 and 23 IU per deciliter (median, 24 IU 
per deciliter) at the end of year 2.
The annualized rate of bleeding events de-
creased by 92%, from a mean of 12.2±15.4 
events per year (median, 8.0 events per year) in 
the year before study entry to a mean of 1.2±2.4 
events per year (median, 0.0 events per year) at 
the end of year 2 (Fig. 3). In the year before study 
entry, 17% of the participants were free from 
bleeding events that led to factor VIII treatment 
for breakthrough bleeding; 2 years after the in-
fusion, 67% of the participants were free from 
bleeding events. In the year before study entry, 
the mean annualized number of factor VIII infu-
sions per participant was 146.5±41.6 (median, 
155.5). At end of year 2, the mean annual use of 
exogenous factor VIII decreased by 95%, to a 
mean of 6.8±15.6 infusions (median, 0.5 infu-
sions) (Fig. 3).
With the exception of Participant 15, all the 
participants in cohort 4 had full resolution of 
bleeding in target joints12 by year 2. Participant 
15 reported 11 of the 12 bleeding events and 
94% of the use of factor VIII that occurred in 
cohort 4 after post-administration week 5.
Factor VIII Levels and Clinical Outcomes
The relationship between factor VIII level and 
bleeding risk is challenging to describe in severe 
hemophilia A, since factor VIII levels fluctuate 
in response to infusions of factor VIII replace-
ment therapy. Data from this study showed an 
asymptotic reduction in the frequency of bleed-
ing events as factor VIII activity levels increased 
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(Fig. 4). This finding is in alignment with previ-
ously published data in populations of patients 
with hemophilia A of differing severities13 and 
provides further evidence of equivalent biologic 
activity between the AAV5-hFVIII-SQ transgene 
and native factor VIII.
At end of year 3, the levels of factor VIII that 
were measured by the more conservative chro-
mogenic assay placed the participants in cohort 
3 into categories of hemophilia A that were de-
fined as nonhemophilic (one participant), mild 
(five participants), and moderate (one partici-
pant). At this same time point, all the partici-
pants were no longer receiving prophylaxis, had 
a mean annualized rate of bleeding events of 0, 
and had full resolution of bleeding in target 
joints.
 Individual Participant Profiles
 Decrease and Persistence in Factor VIII Expression
Individual patterns of factor VIII expression 
commonly showed slow initial increases in cir-
culating factor VIII levels over the first 20 to 28 
weeks, followed by peaking and then a gradu-
ally slowing decrease (Figs. 1 and 2 and Figs. S1 
and S2). Underlying this trend were three detect-
able stages of DNA microdistribution and struc-
tural dynamics, as assessed with the use of 
whole blood cells as an observable proxy for 
hepatocytes and with the use of droplet digital 
polymerase chain reaction to detect the forma-
tion of full-length expression cassettes and in-
verted-terminal-repeat fusion events, respectively 
(Fig. S3).
Slow initial increases in factor VIII expression 
are consistent with preclinical studies of AAV5-
hFVIII-SQ8 and other AAV5 vectors14 and are due 
in part to rates of viral uncoating and DNA de-
livery.15 During the slow increase in factor VIII 
protein expression, we observed an approximately 
4-log decline in non–full-length factor VIII DNA 
Figure 3 (facing page). Annualized Rates of Bleeding 
Events and Factor VIII Use.
Shown are the annualized rates of bleeding events 
among participants in cohort 3 in aggregate (Panel A) 
and individually (Panel B), as well as the factor VIII uti-
lization data for cohort 3 in aggregate (Panel C) and 
individually (Panel D). Data in Panels A and B are shown 
only for the participants who were treated prophylacti-
cally in the year before the start of the study. The rate 
of mean annualized infusions of exogenous factor VIII 
relative to the mean annualized rate of bleeding events 
after week 5 was attributable in part to prophylactic 
factor VIII use during two non–treatment-related sur-
gical events. A total of 10 bleeding events (91% of the 
overall events) and 75 events of factor VIII use (74% of 
the overall events) occurred in Participant 6, who under-
went total knee-replacement surgery for preexisting, 
chronic hemophilic arthropathy and who had the low-
est post-treatment factor VIII activity in the cohort. 
Participant 3 had no bleeding events and 24 events of 
factor VIII use (24% of the overall events), which also 
reflected prophylactic administration during total knee-
replacement surgery for preexisting, chronic hemophilic 
arthropathy. Also shown are the annualized rates of 
bleeding events among participants in cohort 4 in ag-
gregate (Panel E) and individually (Panel F), as well as 
the factor VIII utilization data for cohort 4 in aggregate 
(Panel G) and individually (Panel H). Of 12 bleeding 
events and 52 events of factor VIII use that occurred 
after week 5 in this cohort, 11 bleeding events (92% 
of the overall events) and 49 events of factor VIII use 
(94% of the overall events) occurred in Participant 15, 
who consistently had lower factor VIII levels than the 
rest of the cohort. Interrogation of this participant’s 
background information (including medical history, 
concomitant medication use, and laboratory findings) 
did not reveal any clear reason for factor VIII expres-
sion levels being lower than in cohort counterparts 
(Fig. S1).
Figure 4. Number of Observed and Predicted Bleeding Events, According to 
Factor VIII Activity Level.
Shown are the numbers of participant-reported treated bleeding events ac-
cording to factor VIII activity level in all the participants. Open circles rep-
resent the number of observed participant-reported treated bleeding events 
and the corresponding factor VIII level (as assessed on chromogenic assay) 
for a single participant within a 4-week window. Predicted values (shaded 
line) are based on negative binomial regression. Two outlying data points 
are observed in this representation. The first corresponds to a mean factor 
VIII level of 20 at weeks 4 to 8 in Participant 4; the per-week values during 
this time were 5 IU per deciliter, 12 IU per deciliter, 152 IU per deciliter, 
and 49 IU per deciliter. Factor VIII was administered at the point when the 
levels were approximately 5 IU per deciliter, in response to a muscular 
bleeding event. The second outlier corresponds to a self-administration 
of factor VIII by Participant 14 in response to a traumatic ankle injury, at 
circulating factor VIII levels of 53 IU per deciliter.
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coinciding with the life span of short-lived 
granulocytes, followed by a less-rapid decline 
associated with the life span of nonnucleated red 
cells (Fig. S4). Despite bulk loss of vector DNA 
in this period of increasing protein expression, 
the portion of transgene DNA in peripheral-
blood mononuclear cells showed stronger persis-
tence, presumably owing to an observed simul-
taneous increase in the percentage of stable 
circularized DNA episomes in the nuclei of 
peripheral-blood mononuclear cells (Fig. S4), a 
finding that confirms a previously established 
mechanism of vector DNA persistence.16-18
Finally, a slowing decrease in factor VIII ex-
pression was observed in years 2 and 3, which 
potentially reflects a gradual turnover of stable, 
expression-competent DNA in longer-lived, nucle-
ated cells. Thus, persistent transgene expression 
through years 2 and 3 was consistent with the 
establishment of stable episomal transgenes de-
tected in observable nucleated cells during year 1. 
Hepatocytes are presumed to be the predominant 
host of longer-term AAV5-hFVIII-SQ–derived 
factor VIII protein expression owing to AAV5 
tropism and the use of a liver-specific promoter; 
liver-biopsy studies are under way.
Host Response Variability
Each biologic step occurring between the admin-
istration of gene therapy and transgene expres-
sion may vary among hosts.16,17 Responses to gene 
therapy can also vary between serotypes and 
transgenes. This variation is particularly likely 
for factor VIII, owing to manufacturing and 
processing complexities caused by its large size 
and extensive post-translational modifications.19,20 
Indeed, factor VIII expression shows variability 
within and among healthy adults.21-26 Mecha-
nisms of gene-therapy response variability due 
to individual-specific biologic variables remain 
to be understood, but an initial investigation 
into participant-specific biologic variables was 
undertaken within the limitations of the small 
sample population studied here. Individual par-
ticipant profiles and medical records were inter-
rogated to provide information about causality 
of variability in factor VIII expression (Fig. 1 and 
Fig. S1).
In cohort 3, all the participants had a mean 
factor VIII level within the ranges considered to 
indicate mild hemophilia A or nonhemophilic 
status, except for Participant 6, who had a mean 
factor VIII level that was within the range con-
sidered to indicate moderate hemophilia A, accord-
ing to the chromogenic assay (4 IU per deciliter), 
or considered to indicate the mild range, accord-
ing to the one-stage assay (6 IU per deciliter). 
Similarly, in cohort 4, all the participants had a 
mean factor VIII expression level associated with 
the mild range of hemophilia in year 2. However, 
Participant 15 (who had a mean factor VIII level 
of 6 IU per deciliter, according to the chromo-
genic assay) had the majority of the post-admin-
istration bleeding events and factor VIII utiliza-
tion in the cohort, as well as having the only 
target joint with bleeding that did not resolve in 
the study. Individual response profiles and med-
ical histories for Participants 6 and 15 were 
compared with those of the cohort counterparts 
(Fig. S1). Participant 6 had an early elevation in 
the alanine aminotransferase level that was 
treated with on-demand glucocorticoids before 
the planned initiation of prophylactic glucocorti-
coids; however, Participant 9 had a similar expe-
rience, including initiation of on-demand gluco-
corticoids before the planned initiation of 
prophylactic glucocorticoids, and had a mean 
factor VIII expression level that was nine times 
as high as that in Participant 6, with a similar 
clinical benefit being observed in both partici-
pants. Participant 15 had no potentially causal 
differences from other participants in various 
factors such as the time until the initiation of 
glucocorticoids after the elevation in the alanine 
aminotransferase level, glucocorticoid dosage, 
or glucocorticoid tapering. An examination of 
all the response profiles broadly suggests that 
glucocorticoids may have assisted in rescue or 
protection of factor VIII levels during elevations 
of the alanine aminotransferase level (in Partici-
pants 3, 5, 8, 9, 11, 12, and 14) and in resolution 
of elevated alanine aminotransferase levels (in 
Participants 3, 4, 5, 12, 14, and 15). The eleva-
tions in the alanine aminotransferase level ap-
peared to have been temporally associated with 
decreases in factor VIII expression in some par-
ticipants (Participants 4, 5, 7, and 8).
Additional variables under assessment in-
cluded: the timing, dose, duration, and tapering 
of the glucocorticoid regimen; the historical an-
nualized rate of bleeding events, pharmacokinet-
ics, and type of previous use of exogenous factor 
VIII; concomitant medications; ABO blood type; 
von Willebrand factor level; HLA type; age; body-
n engl j med 382;1 nejm.org January 2, 2020 39
AAV5-hFVIII-SQ Gene Ther apy for Hemophilia A
mass index and weight; liver health as assessed 
by means of C-reactive protein level, hepatitis 
status, liver-function tests, and FibroTest; vector 
infusion variables, including the type of pump, 
duration, and presence of extravasation; and 
adverse events.
Owing to the small sample size, no specific 
variables contributing to individual factor VIII 
levels could be identified in this study. However, 
trends in the timing of glucocorticoid adminis-
tration relative to elevations in the alanine amino-
transferase level are suggestive.
Discussion
This study of AAV5-hFVIII-SQ showed that an 
oversized gene could be packaged into an AAV 
capsid, achieve full length and inverted-terminal-
repeat fusion within cell nuclei, and express 
functional transgene to yield sustained clinical 
benefit. These data show multiyear factor VIII 
expression and effective control of bleeding in 
13 men with severe hemophilia A. Within the 
most recent year of follow-up, participants had 
factor VIII levels within the nonhemophilic 
range (1 participant), the mild hemophilic range 
(11 participants), and the moderate hemophilic 
range (1 participant), as measured by the chro-
mogenic assay (which is more conservative than 
the one-stage assay).
No new safety events were noted.1 All eleva-
tions in the alanine aminotransferase level were 
mild, nonserious, and transient, and there were 
no symptoms or sequelae suggestive of clinically 
significant hepatocyte injury or liver dysfunction. 
No cellular immune responses to factor VIII or 
AAV5 capsid were consistently detected in any 
participant. No development of factor VIII inhibi-
tors or other factor VIII antibodies was detected.
Liver health was evaluated to assess the bur-
den on hepatocytes to produce B-domain–deleted 
factor VIII and eliminate viral capsids after 
transgene DNA delivery or fragmented vector 
DNA. The levels of alanine aminotransferase and 
γ-glutamyltransferase did not indicate ongoing 
liver damage, and, in the absence of detectable 
cellular immune response, decreases in factor 
VIII expression and elevations in the alanine 
aminotransferase level cannot be attributed to 
abnormal hepatocyte turnover. No evidence of 
endoplasmic reticulum stress was noted at doses 
explored in this study, but studies in mice and 
nonhuman primates have shown that AAV-medi-
ated constructs containing factor VIII and a 
stronger promoter than that of AAV5-hFVIII-SQ 
can cause endoplasmic reticulum stress at higher 
doses than those studied here.8,27 Liver-biopsy 
studies involving humans will be necessary to 
confirm the translatability of these results.
Participants in cohorts 3 and 4 had a slow 
increase to varying peak levels of factor VIII ex-
pression, followed by decreasing rates of decline 
over time, with exceptions. Variability in factor 
VIII levels has been observed in healthy persons, 
which suggests that normal biologic variables 
could contribute to observed differences in fac-
tor VIII expression through the activities of trans-
acting genetic modifiers, age, von Willebrand 
factor level, lipoprotein receptor–related protein 
activity, and metabolism.21-26 An initial investiga-
tion into potential mechanisms underlying re-
sponse variability yielded no significant signals, 
but observed trends suggest that glucocorticoid 
regimens may play a role. Findings from this 
study and others underscore the importance of 
achieving a high initial transgene expression.
Additional mechanistic hypotheses of vari-
ability deserve further exploration and relate to 
the complexity and potential stress of factor VIII 
assembly and folding, host cell type, potential 
destabilization or silencing of nuclear factor VIII 
DNA, potential threshold response,28 and hepato-
cyte AAV receptor polymorphisms and distribu-
tion. Finally, lifestyle factors such as liver health, 
trauma, metabolism, alcohol consumption, and 
acetaminophen use may introduce variability.
Persistent factor VIII expression is associated 
with the formation of stable, circularized DNA 
in cell nuclei. Experiments in mice have shown 
that factor VIII levels in plasma are representa-
tive of vector DNA levels in hepatocytes,8 but 
there are limitations to studying nucleated blood 
cells as a proxy for hepatocyte transduction, ow-
ing in part to potential differences in cell-type–
specific transduction mechanisms. To better 
understand DNA structural dynamics that may 
underlie persistent expression, transduction in 
hepatocytes will need to be specifically studied 
by means of liver biopsy.
These long-term follow-up data contribute to 
a growing understanding of AAV vector biology 
and to our progress toward a useful treatment 
for persons living with hemophilia A. At the latest 
time point assessed, the 13 participants in co-
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horts 3 and 4 in our study had substantial reduc-
tions in the incidence of bleeding events, had 
resolution of bleeding in target joints (in 12 par-
ticipants), and had complete cessation of factor 
VIII prophylaxis. Monitoring of these partici-
pants is continuing; efficacy and safety are be-
ing examined in an ongoing expanded phase 3 
study (ClinicalTrials.gov number, NCT03370913; 
EudraCT number, 2017 - 003215 - 19).
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